You are being redirected to the story the piece of content is found in so you can read it in context. Please click the following link if you are not automatically redirected within a couple seconds:
To patent or not to patent? the case of Novartis’ cancer drug Glivec in India
Author: Ravinder Gabble & Jillian Clare Kohler, in Global Health (USA), Published on: 6 January 2014
Glivec...produced by the pharmaceutical company Novartis, is prescribed [to treat]...one of the most common blood cancers in eastern countries...[T]he Supreme Court of India gave its final decision...rejecting the appeal of the Swiss...drug manufacturer...[T]he Supreme Court stated that even if the bioavailability of the drug was improved, it did not demonstrate enhanced efficacy and that Glivec was not patentable...[T]he drug needs to be taken lifelong…For this reason, along with the fact that 95% of Indians do not possess private health insurance, its pricing plays a critical factor in cancer patients’ ability to access a continuous supply of Glivec for effective treatment...The pricing of cancer treatment is arguably the most important factor in determining India’s position in the case: a monthly dose of the patented version of Glivec…is over three times an average Indian’s annual income...
Related companies: Novartis